ClinicalTrials.gg
CompletedNCT02436096AFFIRMUpdated Feb 7, 2025Results posted

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia

A Phase 3 interventional study of TNX-102 SL Tablet, 2.8mg and Placebo SL Tablet in Fibromyalgia, Myofascial Pain Syndromes and Muscular Diseases, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
519
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
23rd of 320
519 · median 72
Started
2015
with 11 others
Phase 3
55 of 369
2 open now
Registered
204th of 369
by date
Lead sponsor
8 of 369
Tonix Pharmaceuticals, Inc.

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 23rd largest by enrollment of the 320 interventional ones that give a count, is one of 12 that started in 2015, is one of 55 in phase 3, and was the 204th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

The use of low-dose CBP dosed nightly at bedtime for FM was supported by the results of Tonix' TNX-CY-F202 Phase 2b study (also referred to as the BESTFIT Study). The TNX-CY-F202 study provided evidence that TNX-102 SL 2.8 mg dosed nightly results in beneficial effects upon pain, sleep and other FM symptomatology.

The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.

03

Conditions studied

  • Fibromyalgia
  • Myofascial Pain Syndromes
  • Muscular Diseases
  • Musculoskeletal Diseases
  • Nervous System Diseases
  • Neuromuscular Diseases
  • Rheumatic Diseases

Keywords

  • Pain
  • Sleep
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Primary Fibromyalgia (2010 ACR criteria)
  • Male or female 18-75 years old
  • For patients with major depressive disorders only: clinically stable, no suicidal risk and stable anti-depressant therapy
  • Willing and able to withdraw specific therapies (ask PI)
  • Medically acceptable form of (female only)
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Arthritis, lupus and other systemic auto-immune diseases
  • Regional or persistent pain that could interfere with assessment of fibromyalgia pain
  • Bipolar and psychotic disorders
  • Increased risk of suicide
  • Significant clinical (cardiac, systemic infection, systemic requirement, drug/alcohol abuse) or laboratory abnormalities.
  • Inability to wash-out specific medications (ask PI)
  • Known to cyclobenzaprine
  • Others: seizure disorders, severe/untreated sleep apnea, >40
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
519 participants (actual)

Study arms

  • Experimental
    TNX-102 SL Tablet, 2.8 mg

    1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks

    Drug: TNX-102 SL Tablet, 2.8mg

  • Placebo comparator
    Placebo SL Tablet

    1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks

    Drug: Placebo SL Tablet

Interventions

  • Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.

    Also known as: Low dose cyclobenzaprine sublingual tablets

  • DrugPlacebo SL Tablet

    Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.

    Also known as: Placebo sublingual tablets

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With ≥30% Pain Improvement

    The primary efficacy endpoint is the proportion of patients with a ≥30% improvement (responder criteria) from baseline to Week 12 in the weekly mean of the daily self-reported 24-hour recall average pain intensity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).

    Time frame: Day 1, Week 12

Secondary outcomes

  1. Patient's Global Impression of Change (PGIC)

    Proportion of patients with a PGIC rating of 1 ("very much improved") or 2 ("much improved") at Week 12. The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates the highest level of worsening.

    Time frame: Week 12

  2. Change From Baseline to Week 12 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score

    The FIQR is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.

    Time frame: Day 1, Week 12

  3. Change From Baseline to Week 12 in the FIQR Function Domain Score

    The FIQR is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.

    Time frame: Day 1, Week 12

  4. Patient Reported Outcomes Measurement System (PROMIS) Sleep Disturbance

    Change from baseline in the PROMIS score for sleep disturbance at Week 12. The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10. Lower T-scores indicate less sleep disturbance.

    Time frame: Day 1, Week 12

  5. Weekly Average of Daily Sleep Quality Diary

    Change from Baseline in the weekly average of the daily diary assessment of sleep quality at Week 12. Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).

    Time frame: Baseline (Day -7 to Day -1), Week 12

  6. Patient Reported Outcomes Measurement System (PROMIS) Fatigue

    Change from Baseline in the PROMIS score for fatigue at Week 12. The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10. Lower T-scores indicate less fatigue.

    Time frame: Day 1, Week 12

  7. Weekly Average of Daily Pain Diary

    Change from baseline to Week 12 in the weekly average of the daily self-reported average pain severity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).

    Time frame: Baseline (Day -7 to Day -1), Week 12

07

Results

Posted Feb 7, 2025

Participant flow

Participant flow — Overall Study
MilestonePlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
Started257262
Completed222203
Not completed3559

Outcome measures

PrimaryProportion of Patients With ≥30% Pain Improvement

The primary efficacy endpoint is the proportion of patients with a ≥30% improvement (responder criteria) from baseline to Week 12 in the weekly mean of the daily self-reported 24-hour recall average pain intensity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).

Time frame:
Day 1, Week 12
Reported as:
Count of participants · Participants
Proportion of Patients With ≥30% Pain Improvement
ParticipantsPlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
Proportion of Patients With ≥30% Pain Improvement5875
SecondaryPatient's Global Impression of Change (PGIC)

Proportion of patients with a PGIC rating of 1 ("very much improved") or 2 ("much improved") at Week 12. The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates the highest level of worsening.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Patient's Global Impression of Change (PGIC)
ParticipantsPlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
Patient's Global Impression of Change (PGIC)4262
SecondaryChange From Baseline to Week 12 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score

The FIQR is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.

Time frame:
Day 1, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score
units on a scalePlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
Change From Baseline to Week 12 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score-8.2 ± 1.13-14.1 ± 1.14
SecondaryChange From Baseline to Week 12 in the FIQR Function Domain Score

The FIQR is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.

Time frame:
Day 1, Week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 in the FIQR Function Domain Score
units on a scalePlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
Change From Baseline to Week 12 in the FIQR Function Domain Score-4.4 ± 1.15-10.3 ± 1.16
SecondaryPatient Reported Outcomes Measurement System (PROMIS) Sleep Disturbance

Change from baseline in the PROMIS score for sleep disturbance at Week 12. The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10. Lower T-scores indicate less sleep disturbance.

Time frame:
Day 1, Week 12
Reported as:
Least squares mean · T-score
Patient Reported Outcomes Measurement System (PROMIS) Sleep Disturbance
T-scorePlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
Patient Reported Outcomes Measurement System (PROMIS) Sleep Disturbance-4.7 ± .53-8.0 ± .54
SecondaryWeekly Average of Daily Sleep Quality Diary

Change from Baseline in the weekly average of the daily diary assessment of sleep quality at Week 12. Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).

Time frame:
Baseline (Day -7 to Day -1), Week 12
Reported as:
Least squares mean · units on a scale
Weekly Average of Daily Sleep Quality Diary
units on a scalePlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
Weekly Average of Daily Sleep Quality Diary-1.0 ± 0.11-1.8 ± 0.11
SecondaryPatient Reported Outcomes Measurement System (PROMIS) Fatigue

Change from Baseline in the PROMIS score for fatigue at Week 12. The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10. Lower T-scores indicate less fatigue.

Time frame:
Day 1, Week 12
Reported as:
Least squares mean · T-score
Patient Reported Outcomes Measurement System (PROMIS) Fatigue
T-scorePlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
Patient Reported Outcomes Measurement System (PROMIS) Fatigue-4.2 ± .47-6.4 ± .47
SecondaryWeekly Average of Daily Pain Diary

Change from baseline to Week 12 in the weekly average of the daily self-reported average pain severity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).

Time frame:
Baseline (Day -7 to Day -1), Week 12
Reported as:
Least squares mean · units on a scale
Weekly Average of Daily Pain Diary
units on a scalePlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
Weekly Average of Daily Pain Diary-1.0 ± 0.11-1.5 ± 0.11

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo SL Tablet0/256 (0%)4/256 (1.6%)17/256 (6.6%)
TNX-102 SL Tablet, 2.8 mg0/262 (0%)3/262 (1.1%)132/262 (50.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
DizzinessNervous system disorders1/2560/262
PresyncopeNervous system disorders1/2560/262
Atrial FibrillationCardiac disorders1/2560/262
Non-cardiac Chest PainGeneral disorders1/2560/262
Foot FractureInjury, poisoning and procedural complications1/2560/262
SeizureNervous system disorders0/2561/262
PneumoniaInfections and infestations0/2561/262
Suicide AttemptPsychiatric disorders0/2561/262
Most frequent other events
Most frequent other events
EventPlacebo SL TabletTNX-102 SL Tablet, 2.8 mg
Hypoaesthesia OralGastrointestinal disorders2/256105/262
GlossodyniaGastrointestinal disorders4/25624/262
Paraesthesia OralGastrointestinal disorders3/25620/262
Product Taste AbnormalProduct Issues2/25616/262
FatigueGeneral disorders6/25615/262

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo SL TabletTNX-102 SL Tablet, 2.8 mgTotal
Mean47.8 ± 11.2047.8 ± 11.1647.8 ± 11.17
Sex: Female, Male
Sex: Female, Male(Participants)Placebo SL TabletTNX-102 SL Tablet, 2.8 mgTotal
Female247252499
Male101020
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo SL TabletTNX-102 SL Tablet, 2.8 mgTotal
Hispanic or Latino213152
Not Hispanic or Latino236231467
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo SL TabletTNX-102 SL Tablet, 2.8 mgTotal
American Indian or Alaska Native224
Asian516
Native Hawaiian or Other Pacific Islander011
Black or African American271138
White221242463
More than one race123
Unknown or Not Reported134
Region of Enrollment
Region of Enrollment(participants)Placebo SL TabletTNX-102 SL Tablet, 2.8 mgTotal
United States257262519
08

Study locations

35 sites
  • Birmingham, Alabama 35216, United States
  • Phoenix, Arizona 85032, United States
  • Sacramento, California 95825, United States
  • San Diego, California 92103, United States
  • Brandon, Florida 33511, United States
  • DeLand, Florida 32720, United States
  • Lakeland, Florida 33805, United States
  • Ocala, Florida 34471, United States
  • Orlando, Florida 32806, United States
  • Tampa, Florida 33613, United States
  • Tampa, Florida 33614, United States
  • West Palm Beach, Florida 33409, United States
  • Columbus, Georgia 31904, United States
  • Smyrna, Georgia 30080, United States
  • Evansville, Indiana 47714, United States
  • North Dartmouth, Massachusetts 02747, United States
  • Ann Arbor, Michigan 48104, United States
  • Jackson, Mississippi 39202, United States
  • Williamsville, New York 14221, United States
  • Cincinnati, Ohio 45206, United States
  • Columbus, Ohio 43212, United States
  • Middleburg Heights, Ohio 44130, United States
  • Medford, Oregon 97504, United States
  • Portland, Oregon 97210, United States
  • Allentown, Pennsylvania 18104, United States
  • Warwick, Rhode Island 02888, United States
  • Greer, South Carolina 29650, United States
  • Mount Pleasant, South Carolina 29464, United States
  • Dallas, Texas 75231, United States
  • Salt Lake City, Utah 84102, United States
  • Charlottesville, Virginia 22911, United States
  • Norfolk, Virginia 23507, United States
  • Bellevue, Washington 98007, United States
  • Seattle, Washington 98104, United States
  • Kenosha, Wisconsin 53142, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2025, 8 years 5 months after primary completion. A results delay was requested in Dec 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2015
First posted
May 6, 2015
Start
Apr 2015
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results delay requested
Dec 5, 2017
Results first posted
Feb 7, 2025
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02436096
Responsible party
Sponsor
First posted
May 6, 2015
Start date
Apr 2015
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
Feb 7, 2025
Last update
Feb 7, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion